New Delhi: GlaxoSmithKline (GSK) Pharmaceuticals Limited has announced the resignation of its Whole-time Director and Chief Financial Officer, Juby Chandy, following his appointment as Finance Head for the Asia Pacific region at the company.The resignation, which was formally communicated to the stock exchanges under SEBI Listing Regulations, comes into effect from the close of business hours on March 11, 2026. The company disclosed that the move is in line with regulatory requirements and follows an earlier announcement made on March 2, 2026.In his resignation letter addressed to the Board of Directors, Chandy stated that he is stepping down from his roles due to his new regional responsibility within GSK. He also requested the Board to take the resignation on record and complete all necessary filings with the relevant government authorities and regulatory bodies.Also Read: GSK Licenses Linerixibat to Alfasigma in Deal Worth Up to USD 690 MillionChandy expressed gratitude to the Board of Directors and the Managing Director for their continuous support and guidance during his tenure. He described his time at the company as a privilege and extended his best wishes for the continued growth and success of GSK India.The company, in its official communication dated March 16, 2026, confirmed receipt of the resignation and stated that it has submitted the required disclosure to both BSE and NSE.According to the company communication, the resignation aligns with internal leadership restructuring following Chandy’s elevation to a broader regional role within the organization.Also Read: AI Reshapes Drug Development Workflows, But Breakthrough Molecules Still Elusive